Neuronetics to be Acquired by HealthTronics Affiliate
Ticker: STIM · Form: 8-K · Filed: Aug 14, 2024 · CIK: 1227636
| Field | Detail |
|---|---|
| Company | Neuronetics, Inc. (STIM) |
| Form Type | 8-K |
| Filed Date | Aug 14, 2024 |
| Risk Level | medium |
| Pages | 6 |
| Reading Time | 7 min |
| Key Dollar Amounts | $0.01 |
| Sentiment | neutral |
Sentiment: neutral
Topics: acquisition, merger, medical-devices
TL;DR
Neuronetics is getting bought by HealthTronics affiliate, deal expected Q4 2024.
AI Summary
On August 13, 2024, Neuronetics, Inc. announced a definitive agreement to be acquired by an affiliate of HealthTronics, Inc. The transaction is expected to close in the fourth quarter of 2024, subject to customary closing conditions. This acquisition will combine two leaders in urology and oncology.
Why It Matters
This acquisition signals consolidation in the medical device sector, potentially impacting competition and innovation in urology and oncology treatments.
Risk Assessment
Risk Level: medium — The acquisition is subject to customary closing conditions, which introduces a degree of uncertainty until the deal is finalized.
Key Players & Entities
- Neuronetics, Inc. (company) — Registrant and target company
- HealthTronics, Inc. (company) — Acquiring entity's affiliate
- Fourth Quarter of 2024 (date) — Expected closing period of the acquisition
FAQ
What is the primary purpose of this Form 8-K filing?
This Form 8-K is filed to report a definitive agreement for the acquisition of Neuronetics, Inc. by an affiliate of HealthTronics, Inc.
Who is acquiring Neuronetics, Inc.?
Neuronetics, Inc. is being acquired by an affiliate of HealthTronics, Inc.
When is the acquisition expected to be completed?
The acquisition is expected to close in the fourth quarter of 2024.
What conditions must be met for the acquisition to close?
The acquisition is subject to customary closing conditions.
What is the strategic rationale behind this acquisition?
The filing states that the acquisition will combine two leaders in urology and oncology.
Filing Stats: 1,780 words · 7 min read · ~6 pages · Grade level 17 · Accepted 2024-08-13 18:27:29
Key Financial Figures
- $0.01 — ange on which registered Common Stock ($0.01 par value) STIM The Nasdaq Global M
Filing Documents
- d835019d8k.htm (8-K) — 33KB
- d835019dex991.htm (EX-99.1) — 20KB
- g835019ex99_1s10g1.jpg (GRAPHIC) — 98KB
- g835019ex99_1s11g1.jpg (GRAPHIC) — 84KB
- g835019ex99_1s12g1.jpg (GRAPHIC) — 87KB
- g835019ex99_1s13g1.jpg (GRAPHIC) — 90KB
- g835019ex99_1s14g1.jpg (GRAPHIC) — 25KB
- g835019ex99_1s15g1.jpg (GRAPHIC) — 60KB
- g835019ex99_1s16g1.jpg (GRAPHIC) — 29KB
- g835019ex99_1s1g1.jpg (GRAPHIC) — 92KB
- g835019ex99_1s2g1.jpg (GRAPHIC) — 182KB
- g835019ex99_1s3g1.jpg (GRAPHIC) — 88KB
- g835019ex99_1s4g1.jpg (GRAPHIC) — 72KB
- g835019ex99_1s5g1.jpg (GRAPHIC) — 92KB
- g835019ex99_1s6g1.jpg (GRAPHIC) — 80KB
- g835019ex99_1s7g1.jpg (GRAPHIC) — 106KB
- g835019ex99_1s8g1.jpg (GRAPHIC) — 43KB
- g835019ex99_1s9g1.jpg (GRAPHIC) — 72KB
- 0001193125-24-199931.txt ( ) — 1975KB
- stim-20240813.xsd (EX-101.SCH) — 3KB
- stim-20240813_lab.xml (EX-101.LAB) — 17KB
- stim-20240813_pre.xml (EX-101.PRE) — 11KB
- d835019d8k_htm.xml (XML) — 3KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit 99.1 Neuronetics, Inc. Canaccord Genuity Annual Growth Conference Presentation dated August 14, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 2
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: August 13, 2024 NEURONETICS, INC. By: /s/ Stephen Furlong Stephen Furlong EVP, Chief Financial Officer and Treasurer 3